Hypoxic Exosomes Drive CCL26 in HNSCC - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Hypoxic Exosomes Drive CCL26 in HNSCC

Hypoxia-induced vesicles reshape endothelial signaling and may promote tumor-associated phenotypes in head and neck squamous cell carcinoma

  • By

  • Andrea Surnit

  • April 13, 2026

  • 3 min

Share

Objective:

To investigate the role of hypoxia-induced tumor-derived exosomes in promoting CCL26 secretion and tumor-associated phenotypes in head and neck squamous cell carcinoma (HNSCC).

Approach:
    Key Findings:
    • Hypoxic exosomes altered protein levels in endothelial secretomes, increasing CCL26.
    • CCL26-enriched secretomes enhanced viability, migration, and invasion of HNSCC cells.
    • Neutralization of CCL26 and genetic silencing of CCR3 reduced tumor-associated phenotypes.
    • CCL26 and hypoxia-inducible factor 1 alpha were higher in tumor vs normal tissues and in metastatic vs primary tumors.
    Interpretation:

    Hypoxia-induced exosomes from HNSCC cells significantly reshape endothelial cell secretomes, primarily through elevated CCL26, which is associated with aggressive tumor characteristics.

    Limitations:
    • Lack of validation under controlled hypoxic chamber conditions.
    • Absence of rescue experiments using recombinant CCL26.
    • No epitope-independent validation of CCL26 neutralization approaches.
    Conclusion:

    Hypoxic exosomes play a crucial role in enhancing CCL26 levels, contributing to tumor progression in HNSCC, warranting further in vivo validation.

    Sources:

Original Source(s)

Hypoxic Exosomes Drive CCL26 in HNSCC

  • by Andrea Surnit

  • April 13, 2026

Related Content

Cell Aging May Predict Future Disease

Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer,  and mortality across three large cohorts.

Can Proteomics Refine Lung Screening?

Proteomic biomarkers improve short-term lung cancer risk assessment.

High-Dose Vitamin C Could Pose Risk in Severe Burns

“High-dose intravenous vitamin C administered early after injury did not reduce organ dysfunction or [mortality] and should not be a treatment in severe burns.”